Jim Kenney criticized the team for trying to make a bigger profit on a new lease proposal for Temple football.
Mayor-elect Jim Kenney met with Temple University officials Thursday.
No health-care organization, including one legally considered nonprofit, wants to make less money. But as costs become more a part of public debate, all organizations are grudgingly searching for ways to justify their place and prices.
The 76ers likely will lose many basketball games this season, but the off-court team business looks promising.
The Federal Trade Commission said Friday that Endo International agreed to sell two generic drugs to satisfy regulators' antitrust concerns created by Endo's proposed $8 billion acquisition of Par Pharmaceutical.
Teva Pharmaceutical Industries Ltd., said Friday it agreed to buy Gecko Health Innovations Inc., a privately-held company that makes software and other products to remind patients to take their respiratory medicine.
NEW YORK - As fantasy football advertisements are pushing aside beer commercials on TV broadcasts of Eagles games, U.S. Rep. Frank Pallone (D., N.J.) is trying on multiple fronts to get equal legal treatment for sports gambling.
Hoping to ride the recent biotechnology stock boom, Regenxbio Inc., a gene-therapy firm with local ties, began selling shares publicly on the NASDAQ stock market Thursday.
Legislation to control rising drug prices was introduced in Congress last week, and federal prosecutors are investigating drug price increases.
The Philadelphia-based American Association for Cancer Research trumpeted progress on the disease in a report released Wednesday, noting that nine new cancer drugs were approved by the Food and Drug Administration in the 12 months ending July 31.
Computer hackers with ill will seem to be lurking around every corner, and health care is not immune.
"The richness of the information means that the cybersecurity threat to health care has increased," Michael Ebert, KPMG partner and health-care leader at the firm's cyber practice, wrote in a report this week. "The magnitude of the threat against health-care information has grown exponentially, but the intention or spend in securing that information has not always followed."
GlaxoSmithKline plc and Novartis AG said Friday that they had struck a deal for Novartis to pay GSK at least $300 million, and perhaps more than $1 billion, for the remaining rights to the drug ofatumumab.
Merck & Co. has cut 1,950 jobs in the first six months of the year as part of two cost-cutting programs announced in 2010 and 2013, and the near-term pain might not be over.